The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to artificial intelligence (AI)-based breast and prostate cancer detection tools from RadNet's subsidiaries DeepHealth and Quantib.
DeepHealth's Saige-Dx is a more advanced successor to the company's Saige-Q worklist triage software. It uses AI to automatically identify suspicious lesions in mammograms and assigns a suspicion level to each finding and the entire case.
Quantib Prostate 2.0 is an AI-based software solution that advances an MRI prostate reporting workflow and offers a suite of tools, including AI-based segmentation and volumetry, precise registration and movement correction, one-click segmentation of lesion candidates, PI-RADS scoring support, and standardized reporting.
